# Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

> **NCT00812175** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3371 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00812175
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 3371 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812175, "Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00812175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*